News for Aligos Therapeutics, Inc. (ALGS)

**media[654011]**

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS) a clinical stage biopharmaceutical company focused on improvin

SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”, ”œCompany”), a clinical stage biopharmaceutic

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of 24.64% and 68.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $0.31 million, slightly below the estimated $0.33 million.Net Income: Achieved a net income of $43.1 million, a significant turnaround from a net loss

Aligos Therapeutics (ALGS) disclosed its first-quarter revenue at $311,000, falling short of the anticipated $500,000. The company is progressing with its initi

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”), a clinical stage biotechnology company focused

Lucid Capital has initiated coverage on Aligos Therapeutics (ALGS) with a Buy recommendation and set a price target of $36. The firm expresses strong optimism a

Lucid Capital has begun coverage on Aligos Therapeutics, identified by the ticker (ALGS), with a

**media[608864]**

Florida-based Odyssey Marine Exploration, Inc. (OMEX) is up over 59 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS), a clinical stage biopharmaceutical company focused on impro

**media[577151]**

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”, ”œCompany”), a clinical stage biopharmaceut

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”), a clinical stage biotechnology company focuse

**media[561850]**

Aligos Therapeutics (ALGS) reports Q4 loss of $13.08 per share, missing estimates.